COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.

Int J Chron Obstruct Pulmon Dis · 2023 · PMC10045302 · PMID 36998390

Europe PMC DOI

hedged sentence

0.0660

closest p · 1.3× alpha

0.0660

boldest claim

The sentences

did not reach statistical significancep=0.066so close (0.05 < p ≤ 0.1)

Mean total costs of all moderate COPD-related exacerbation episodes per patient were also lower during follow-up but this difference did not reach statistical significance ($380.43 vs $445.12, p=0.066).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.